Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.67 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694322 | 1.00 | EGLN1 (0.67) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3408574 | 0.99 | EGLN1 (0.66) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3433048 | 0.97 | EGLN1 (0.64) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3402703 | 0.97 | EGLN1 (0.64) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL4531181 | 0.97 | EGLN1 (0.64) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3402818 | 0.94 | EGLN1 (0.61) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3402834 | 0.94 | EGLN1 (0.61) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3408354 | 0.94 | EGLN1 (0.61) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3407310 | 0.94 | EGLN1 (0.60) | EGLN1CYP2C8EGLN2EGLN3KCNH2 | |
| SCHEMBL3430412 | 0.94 | EGLN1 (0.60) | EGLN1CYP2C8EGLN2EGLN3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | claimed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | claimed |
| EP-2257539-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009117269-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | claimed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| WO-2023130140-A2 | PERSONALIZED METHODS OF TREATING CANCER | FAETH THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | ACADEMIA SINICA (TW) | 2023-06-29 | — | — | US | disclosed |
| US-20210369678-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| EP-3860593-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | Akebia Therapeutics Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072645-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | AKEBIA THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2257539-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009117269-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117269-A1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885CYP2C8 393/4885EGLN2 2/4885 |
| US-20210369678-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | SI, CYP2E1, ALPI | EGLN1 601/4885CYP2C8 9/4885EGLN2 570/4885 |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | FABP3, CD14, FABP1 | EGLN1 3840/4885CYP2C8 3026/4885EGLN2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.